These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 18161133

  • 1. [Efficacy and tolerability of once-weekly administration of 35 mg alendronate and 17.5 mg risedronate].
    Kishimoto H.
    Nihon Rinsho; 2007 Nov 28; 65 Suppl 9():365-8. PubMed ID: 18161133
    [No Abstract] [Full Text] [Related]

  • 2. [FACT study].
    Tanaka I, Oshima H.
    Nihon Rinsho; 2007 Nov 28; 65 Suppl 9():280-5. PubMed ID: 18161120
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD.
    J Bone Miner Res; 2009 Apr 28; 24(4):719-25. PubMed ID: 19049326
    [Abstract] [Full Text] [Related]

  • 6. [Efficacy and tolerability of risedronate for the treatment of osteoporosis].
    Kishimoto H.
    Clin Calcium; 2008 Oct 28; 18(10):1417-26. PubMed ID: 18830038
    [Abstract] [Full Text] [Related]

  • 7. Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
    Landfeldt E, Lang A, Robbins S, Ström O.
    Calcif Tissue Int; 2011 Sep 28; 89(3):234-45. PubMed ID: 21695544
    [Abstract] [Full Text] [Related]

  • 8. [Bisphosphonates for osteoporosis].
    Narusawa K, Nakamura T.
    Nihon Rinsho; 2007 Nov 28; 65 Suppl 9():311-5. PubMed ID: 18161123
    [No Abstract] [Full Text] [Related]

  • 9. Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention.
    Bock O, Boerst H, Thomasius FE, Degner C, Stephan-Oelkers M, Valentine SM, Felsenberg D.
    J Musculoskelet Neuronal Interact; 2007 Nov 28; 7(2):144-8. PubMed ID: 17627083
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years.
    Bonnick S, Saag KG, Kiel DP, McClung M, Hochberg M, Burnett SM, Sebba A, Kagan R, Chen E, Thompson DE, de Papp AE.
    J Clin Endocrinol Metab; 2006 Jul 28; 91(7):2631-7. PubMed ID: 16636120
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Unusual subtrochanteric femoral insufficiency fractures associated with the prolonged use of alendronate and risedronate: a report of two cases.
    Angthong C, Angthong W.
    J Med Assoc Thai; 2011 Dec 28; 94 Suppl 7():S214-20. PubMed ID: 22619933
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J, Takeda T, Sato Y.
    Curr Med Res Opin; 2006 May 28; 22(5):919-28. PubMed ID: 16709313
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.
    Hochberg MC.
    Curr Osteoporos Rep; 2008 Sep 28; 6(3):89-94. PubMed ID: 18752769
    [Abstract] [Full Text] [Related]

  • 18. [New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].
    Okazaki R.
    Clin Calcium; 2009 Jan 28; 19(1):30-6. PubMed ID: 19122262
    [Abstract] [Full Text] [Related]

  • 19. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.
    Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, Li Z, Balske A, Lindsay R.
    Calcif Tissue Int; 2002 Aug 28; 71(2):103-11. PubMed ID: 12085156
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
    Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC, Kaur A, Thompson DE, Yates J, Orloff JJ.
    Aging (Milano); 2000 Feb 28; 12(1):1-12. PubMed ID: 10746426
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.